How to microdose GLP-1. - Reddit

What does “microdosing GLP-1” actually mean?

There is no standardized clinical definition of “microdosing” for GLP-1 receptor agonists. In the context of GLP-1 therapy, the term generally refers to using doses lower than what the standard phase-3 clinical trials used — for semaglutide, that’s typically below the 1 mg or 2.4 mg benchmarks; for tirzepatide, below the 10 mg or 15 mg maintenance targets in SURMOUNT.

The rationale is dose-response logic: GLP-1 receptor agonism produces appetite-suppressing and metabolic effects across a range of doses, not just at the ceiling doses studied in weight management trials. Staying at a sub-standard dose can be a deliberate clinical strategy for patients who are:

• Highly GI-sensitive— unable to tolerate escalation to ceiling doses without significant nausea or vomiting.
• Below trial-average body weight, where a lower dose may be sufficient for meaningful effect.
• At their weight management goal and seeking a lower maintenance dose to sustain results.

This is distinct from microdosing as it’s used in psychedelic or nootropic contexts. GLP-1 “microdosing” is not about sub-perceptual effects — it’s about finding the lowest dose that still achieves the management goal with acceptable tolerability.

What does the dose-response data show for lower GLP-1 doses?

Both semaglutide and tirzepatide show clear dose-response relationships in clinical trial data. Higher doses produce greater average weight reduction — but lower doses still produce meaningful effects.

In STEP 5 (semaglutide 2.4 mg over 104 weeks), the trial included a titration phase in which patients spent time at 0.25 mg, 0.5 mg, 1.0 mg, and 1.7 mg before reaching 2.4 mg. Dose-response analyses show that lower doses along this curve still produced weight change — the 1.0 mg dose, for example, produced clinically meaningful results for many patients.

In SURMOUNT-1 (tirzepatide), the 5 mg arm produced an average 15% body weight reduction vs. 20.9% at 15 mg. That’s a real difference — but the 5 mg response is not trivial. For patients whose goal is moderate, the lower dose may be appropriate.

The clinical implication: dose is a variable to be optimized for the individual patient, not a target to always maximize.

Why is GLP-1 microdosing a clinical decision, not a DIY protocol?

The interest in GLP-1 microdosing has generated a cottage industry of online guides specifying exact sub-therapeutic doses — 0.1 mg, 0.25 mg, custom dilutions. This is where the discussion becomes risky.

Compounded GLP-1 agents can be prepared at non-standard concentrations by licensed 503A pharmacies, which makes dose flexibility genuinely possible. But the appropriate dose for an individual depends on their body weight, metabolic history, GI baseline, medications, and goals — factors a prescribing clinician evaluates. Dose titration is also a dynamic process: what’s appropriate at week four may not be appropriate at month six.

Self-directed microdosing carries a specific risk: under-dosed patients may lose insufficient weight to achieve health goals while still experiencing enough GI disruption to affect quality of life, sitting in a suboptimal zone for longer than necessary. Clinician oversight exists precisely to navigate this.

Is GI tolerability better at lower doses?

The main driver of interest in sub-standard dosing is GI tolerability. The GI side effects of GLP-1 agents — nausea, vomiting, diarrhea — are dose-dependent in aggregate. Patients who cannot tolerate escalation to 2.4 mg semaglutide or 15 mg tirzepatide often find lower doses more manageable.

That said, GI sensitivity is highly individual. Some patients experience significant nausea even at 0.25 mg semaglutide; others escalate to ceiling doses without notable GI disruption. The dose-response curve for tolerability is not identical to the dose-response curve for efficacy.

Practical strategies that help at any dose include eating smaller portions, avoiding high-fat foods during the first day post-injection, eating slowly, and not lying down immediately after meals. These measures reduce gastric discomfort independent of dose level.

Is a lower dose useful for maintenance?

A distinct and clinically well-established use case for lower doses is maintenance after weight management goals are met. Patients who reach a target weight at a higher dose sometimes transition to a lower maintenance dose — enough to sustain satiety signaling and prevent return to previous patterns without the intensity of an escalating protocol.

This is genuinely “microdosing” in spirit and is consistent with how other chronic-management drugs are dosed: the dose required to achieve a goal and the dose required to maintain the result are often different. Clinicians who manage GLP-1 patients over longer timelines regularly engage in this kind of dose optimization.

What to ask your clinician

If you’re interested in exploring a sub-standard GLP-1 dose, these are the right questions to bring to a clinician:

• At my current weight and metabolic history, what dose range is likely to be meaningful for my specific goals?
• Given my GI sensitivity, what titration schedule makes sense?
• At what point should I consider staying at a lower dose long-term vs. continuing to escalate?
• What labs or metrics should we track to evaluate whether a lower dose is achieving the goal?

These are clinical conversations, not questions with universal answers. That specificity is exactly what clinician-supervised protocols are built for.

Frequently asked questions